Recent trends in microRNA research into breast cancer with particular focus on the associations between microRNAs and intrinsic subtypes

MicroRNAs (miRNAs) are short non-coding RNAs that regulate the function of target genes at the post-transcriptional phase. miRNAs are considered to have roles in the development, progression and metastasis of cancer. Recent studies have indicated that particular miRNA signatures are correlated with tumor aggressiveness, response to drug therapy and patient outcome in breast cancer. On the other hand, in routine clinical practice, the treatment regimens for breast cancer are determined based on the intrinsic subtype of the primary tumor. Previous studies have shown that miRNA expression profiles of each intrinsic subtypes of breast cancer differ. In hormone receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer, miRNA expressions are found to be correlated with endocrine therapy resistance, progesterone receptor expression and heat shock protein activity. Some miRNAs are associated with resistance to HER2-targeted therapy and HER3 expression in HER2-positive breast cancer. In triple-negative breast cancer, miRNA expressions are found to be associated with BRCA mutations, immune system, epithelial–mesenchymal transition, cancer stem cell properties and androgen receptor expression. As it has been clarified that the expression levels and functions of miRNA differ among the various subtypes of breast cancer, and it is necessary to take account of the characteristics of each breast cancer subtype during research into the roles of miRNA in breast cancer. In addition, the discovery of the roles played by miRNAs in breast cancer might provide new opportunities for the development of novel strategies for diagnosing and treating breast cancer.

[1]  V. Kim,et al.  The Drosha-DGCR8 complex in primary microRNA processing. , 2004, Genes & development.

[2]  F. Slack,et al.  Quantitative analysis of microRNAs in tissue microarrays by in situ hybridization. , 2012, BioTechniques.

[3]  J. Ahn,et al.  Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatment , 2013, British Journal of Cancer.

[4]  Robert D Cardiff,et al.  The transcriptional repressor Snail promotes mammary tumor recurrence. , 2005, Cancer cell.

[5]  Yusuke Yamamoto,et al.  Loss of microRNA-27b contributes to breast cancer stem cell generation by activating ENPP1 , 2015, Nature Communications.

[6]  Arndt Hartmann,et al.  Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients , 2008, Breast Cancer Research.

[7]  A. Caudy,et al.  Role for a bidentate ribonuclease in the initiation step of RNA interference , 2001 .

[8]  C. Croce,et al.  MicroRNA gene expression deregulation in human breast cancer. , 2005, Cancer research.

[9]  A. Citri,et al.  EGF–ERBB signalling: towards the systems level , 2006, Nature Reviews Molecular Cell Biology.

[10]  Q. Mi,et al.  MicroRNA Genes , 2008, Annals of the New York Academy of Sciences.

[11]  T. Druley,et al.  The cyclic AMP pathway is a sex-specific modifier of glioma risk in type I neurofibromatosis patients. , 2015, Cancer research.

[12]  Takahiro Ochiya,et al.  The Roles of MicroRNAs in Breast Cancer , 2015, Cancers.

[13]  S. Gayther,et al.  The Contribution of BRCA1 and BRCA2 to Ovarian Cancer , 2009, Molecular oncology.

[14]  Christopher A. Maher,et al.  A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial–mesenchymal transition , 2011, The Journal of cell biology.

[15]  V. Kim,et al.  The nuclear RNase III Drosha initiates microRNA processing , 2003, Nature.

[16]  K. Zatloukal,et al.  miR‐29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis , 2009, EMBO reports.

[17]  C. Deng,et al.  Tumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155 , 2011, Nature Medicine.

[18]  K. Mimori,et al.  MicroRNA-125a-5p Is an Independent Prognostic Factor in Gastric Cancer and Inhibits the Proliferation of Human Gastric Cancer Cells in Combination with Trastuzumab , 2011, Clinical Cancer Research.

[19]  P. Connell,et al.  The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins , 2000, Nature Cell Biology.

[20]  Junjie Bao,et al.  MiR‐21 regulates epithelial‐mesenchymal transition phenotype and hypoxia‐inducible factor‐1α expression in third‐sphere forming breast cancer stem cell‐like cells , 2012, Cancer science.

[21]  Michael A. Freitas,et al.  In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation , 2013, The Journal of experimental medicine.

[22]  M. Kurosumi,et al.  ER, PgR, Ki67, p27Kip1, and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab , 2015, BMC Cancer.

[23]  Michael F. Clarke,et al.  Downregulation of miRNA-200c Links Breast Cancer Stem Cells with Normal Stem Cells , 2009, Cell.

[24]  L. Sempere,et al.  Critical analysis of the potential for microRNA biomarkers in breast cancer management , 2015, Breast cancer.

[25]  L. Lim,et al.  MicroRNAs in the miR-106b Family Regulate p21/CDKN1A and Promote Cell Cycle Progression , 2008, Molecular and Cellular Biology.

[26]  V. Ambros,et al.  The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14 , 1993, Cell.

[27]  Carsten Denkert,et al.  Clinical relevance of host immunity in breast cancer: from TILs to the clinic , 2016, Nature Reviews Clinical Oncology.

[28]  D. Barh,et al.  Microrna let-7: an emerging next-generation cancer therapeutic , 2010, Current oncology.

[29]  Stijn van Dongen,et al.  miRBase: tools for microRNA genomics , 2007, Nucleic Acids Res..

[30]  Gregory J Goodall,et al.  Epigenetic modulation of the miR-200 family is associated with transition to a breast cancer stem-cell-like state , 2013, Journal of Cell Science.

[31]  Takashi Suzuki,et al.  Identification of androgen-responsive microRNAs and androgen-related genes in breast cancer. , 2013, Anticancer research.

[32]  Jian Zhang,et al.  Exosomal miR-221/222 enhances tamoxifen resistance in recipient ER-positive breast cancer cells , 2014, Breast Cancer Research and Treatment.

[33]  P. M. Das,et al.  Downregulation of miR-342 is associated with tamoxifen resistant breast tumors , 2010, Molecular Cancer.

[34]  M. Kitagawa,et al.  Activation of Cyclin-dependent Kinase 2 (Cdk2) in Growth-stimulated Rat Astrocytes , 1998, The Journal of Biological Chemistry.

[35]  M. Kayani,et al.  Role of miRNAs in breast cancer. , 2011, Asian Pacific journal of cancer prevention : APJCP.

[36]  G. Goodall,et al.  The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1 , 2008, Nature Cell Biology.

[37]  S. Wiseman,et al.  HER-3 Overexpression Is Prognostic of Reduced Breast Cancer Survival: A Study of 4046 Patients , 2010, Annals of surgery.

[38]  J. Pietenpol,et al.  Identification and use of biomarkers in treatment strategies for triple‐negative breast cancer subtypes , 2014, The Journal of pathology.

[39]  Sun-Mi Park,et al.  Suppression of miRNA-708 by polycomb group promotes metastases by calcium-induced cell migration. , 2013, Cancer cell.

[40]  Domenico Coppola,et al.  MicroRNA-221/222 Negatively Regulates Estrogen Receptorα and Is Associated with Tamoxifen Resistance in Breast Cancer* , 2008, Journal of Biological Chemistry.

[41]  C. Croce,et al.  MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review , 2012, EMBO molecular medicine.

[42]  M. Berger,et al.  Lapatinib plus capecitabine for HER2-positive advanced breast cancer. , 2006, The New England journal of medicine.

[43]  Israel Steinfeld,et al.  miRNA-mRNA Integrated Analysis Reveals Roles for miRNAs in Primary Breast Tumors , 2011, PloS one.

[44]  C. Perou,et al.  Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[45]  F. Yu,et al.  Reduced miR-128 in Breast Tumor–Initiating Cells Induces Chemotherapeutic Resistance via Bmi-1 and ABCC5 , 2011, Clinical Cancer Research.

[46]  Katie Podshivalova,et al.  MicroRNA regulation of T-lymphocyte immunity: modulation of molecular networks responsible for T-cell activation, differentiation, and development. , 2013, Critical reviews in immunology.

[47]  C. Benz,et al.  Coordinate Suppression of ERBB2 and ERBB3 by Enforced Expression of Micro-RNA miR-125a or miR-125b* , 2007, Journal of Biological Chemistry.

[48]  Christopher P Evans,et al.  An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells , 2007, Proceedings of the National Academy of Sciences.

[49]  M. Gorospe,et al.  miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. , 2011, Molecular cell.

[50]  Lixia Diao,et al.  Metastasis is regulated via microRNA-200/ZEB1 axis control of tumor cell PD-L1 expression and intratumoral immunosuppression , 2014, Nature Communications.

[51]  V. Kim,et al.  Regulation of microRNA biogenesis , 2014, Nature Reviews Molecular Cell Biology.

[52]  C. Caldas,et al.  Micro‐RNAs and breast cancer , 2010, Molecular oncology.

[53]  R. Shiekhattar,et al.  The Microprocessor complex mediates the genesis of microRNAs , 2004, Nature.

[54]  Ignace Vergote,et al.  Dysregulation of microRNAs in breast cancer and their potential role as prognostic and predictive biomarkers in patient management , 2015, Breast Cancer Research.

[55]  Junhua Wu,et al.  Diverse roles of miR-29 in cancer (review). , 2014, Oncology reports.

[56]  Jin-hai Tang,et al.  miR-342 is associated with estrogen receptor-α expression and response to tamoxifen in breast cancer , 2013, Experimental and therapeutic medicine.

[57]  F. Ferrari,et al.  A MicroRNA Targeting Dicer for Metastasis Control , 2010, Cell.

[58]  Hong Ren,et al.  miRNA-205 affects infiltration and metastasis of breast cancer. , 2013, Biochemical and biophysical research communications.

[59]  R. Hartley,et al.  MicroRNA-125a represses cell growth by targeting HuR in breast cancer , 2009, RNA biology.

[60]  M. Ghosh,et al.  The Chaperone-assisted E3 Ligase C Terminus of Hsc70-interacting Protein (CHIP) Targets PTEN for Proteasomal Degradation* , 2012, The Journal of Biological Chemistry.

[61]  S. Sleijfer,et al.  MicroRNA-30c expression level is an independent predictor of clinical benefit of endocrine therapy in advanced estrogen receptor positive breast cancer , 2011, Breast Cancer Research and Treatment.

[62]  R. Bast,et al.  Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients , 2012, Cancer.

[63]  Q. Meng,et al.  Downregulation of miR-221/222 enhances sensitivity of breast cancer cells to tamoxifen through upregulation of TIMP3 , 2014, Cancer Gene Therapy.

[64]  M. Pichler,et al.  The Role of MicroRNAs in Breast Cancer Stem Cells , 2013, International journal of molecular sciences.

[65]  김남희,et al.  A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial-mesenchymal transition , 2011 .

[66]  L. Naldini,et al.  A role for miR-155 in enabling tumor-infiltrating innate immune cells to mount effective antitumor responses in mice. , 2013, Blood.

[67]  B. White,et al.  Coordinate Regulation of FOXO1 by miR-27a, miR-96, and miR-182 in Breast Cancer Cells , 2009, The Journal of Biological Chemistry.

[68]  Hyunsuk Shim,et al.  Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. , 2010, Biochemical pharmacology.

[69]  Anthony Fyles,et al.  MicroRNA-301 mediates proliferation and invasion in human breast cancer. , 2011, Cancer research.

[70]  L. Bégin,et al.  Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. , 2004, Journal of the National Cancer Institute.

[71]  C. Perou,et al.  Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  G Viale,et al.  Pathological and molecular diagnosis of triple-negative breast cancer: a clinical perspective. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[73]  W. Gallagher,et al.  miRNA dysregulation in breast cancer. , 2013, Cancer research.

[74]  Yate-Ching Yuan,et al.  The role of microRNA-128a in regulating TGFbeta signaling in letrozole-resistant breast cancer cells , 2010, Breast Cancer Research and Treatment.

[75]  N. Hynes,et al.  ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling , 1997, The EMBO journal.

[76]  U. Kutay,et al.  Nuclear Export of MicroRNA Precursors , 2004, Science.

[77]  Y Pawitan,et al.  Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer , 2013, Oncogene.

[78]  L. Holmberg,et al.  Integrated genomic analysis of triple-negative breast cancers reveals novel microRNAs associated with clinical and molecular phenotypes and sheds light on the pathways they control , 2013, BMC Genomics.

[79]  L. Molinero,et al.  Abstract 2859: Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC) , 2015 .

[80]  Z. Werb,et al.  GATA3 suppresses metastasis and modulates the tumour microenvironment by regulating microRNA-29b expression , 2013, Nature Cell Biology.

[81]  J. Thigpen,et al.  Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer , 2012 .

[82]  B. Jacobsen,et al.  Progesterone downregulation of miR-141 contributes to expansion of stem-like breast cancer cells through maintenance of progesterone receptor and Stat5a , 2014, Oncogene.

[83]  C. Benz,et al.  Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies , 2006, Molecular Cancer.

[84]  Kedar S Vaidya,et al.  Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis. , 2009, Cancer research.

[85]  L. Chow,et al.  Down-regulation of heat-shock protein 70 (HSP-70) correlated with responsiveness to neoadjuvant aromatase inhibitor therapy in breast cancer patients. , 2010, Anticancer research.

[86]  R. Gelber,et al.  Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[87]  Olga Kovalchuk,et al.  Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin , 2008, Molecular Cancer Therapeutics.

[88]  Leonard D. Goldstein,et al.  MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype , 2007, Genome Biology.

[89]  P. Khosravi-Shahi,et al.  Metastatic triple negative breast cancer: Optimizing treatment options, new and emerging targeted therapies , 2018, Asia-Pacific journal of clinical oncology.

[90]  Y. Bignon,et al.  Identification of miR-10b, miR-26a, miR-146a and miR-153 as potential triple-negative breast cancer biomarkers , 2015, Cellular Oncology.

[91]  S. Yeh,et al.  Abnormal Mammary Gland Development and Growth Retardation in Female Mice and MCF7 Breast Cancer Cells Lacking Androgen Receptor , 2003, The Journal of experimental medicine.

[92]  B. Seliger,et al.  The role of microRNAs in the control of innate immune response in cancer. , 2014, Journal of the National Cancer Institute.

[93]  J. Benítez,et al.  MicroRNA expression signatures for the prediction of BRCA1/2 mutation‐associated hereditary breast cancer in paraffin‐embedded formalin‐fixed breast tumors , 2014, International journal of cancer.

[94]  Ignace Vergote,et al.  Expression profiling of cancerous and normal breast tissues identifies microRNAs that are differentially expressed in serum from patients with (metastatic) breast cancer and healthy volunteers , 2012, Breast Cancer Research.

[95]  G. Calin,et al.  miR-342 Regulates BRCA1 Expression through Modulation of ID4 in Breast Cancer , 2014, PloS one.

[96]  Suhwan Chang,et al.  BRCA1 and MicroRNAs: Emerging networks and potential therapeutic targets , 2012, Molecules and cells.

[97]  W. Gerald,et al.  An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen , 2006, Oncogene.

[98]  C. Croce,et al.  microRNA-205 regulates HER3 in human breast cancer. , 2009, Cancer research.

[99]  Monilola A. Olayioye,et al.  A global microRNA screen identifies regulators of the ErbB receptor signaling network , 2015, Cell Communication and Signaling.

[100]  R. Lin,et al.  MicroRNA and HER2-overexpressing Cancer , 2013, MicroRNA.

[101]  Carsten Denkert,et al.  Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[102]  J. Lieberman,et al.  let-7 Regulates Self Renewal and Tumorigenicity of Breast Cancer Cells , 2007, Cell.

[103]  Hua Zhao,et al.  A functional polymorphism in the miR-146a gene and age of familial breast/ovarian cancer diagnosis. , 2008, Carcinogenesis.

[104]  A. Thor,et al.  Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells. , 2015, International journal of clinical and experimental pathology.

[105]  B. Jacobsen,et al.  Progestin regulated miRNAs that mediate progesterone receptor action in breast cancer , 2012, Molecular and Cellular Endocrinology.

[106]  Anton J. Enright,et al.  Requirement of bic/microRNA-155 for Normal Immune Function , 2007, Science.

[107]  R. Weinberg,et al.  Tumour invasion and metastasis initiated by microRNA-10b in breast cancer , 2007, Nature.

[108]  Bolin Liu,et al.  Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells , 2013, Cell Death and Disease.

[109]  Lin Zhao,et al.  MiR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2). , 2013, Cancer letters.

[110]  J. Underwood.  Lymphoreticular infiltration in human tumours: prognostic and biological implications: a review. , 1974, British Journal of Cancer.

[111]  Chang Gong,et al.  Up-regulation of miR-21 Mediates Resistance to Trastuzumab Therapy for Breast Cancer* , 2011, The Journal of Biological Chemistry.

[112]  Christophe Lemetre,et al.  MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer , 2009, Breast Cancer Research.

[113]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[114]  Stefan Michiels,et al.  Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[115]  L. Tutar,et al.  Regulation of Heat Shock Proteins by miRNAs in human breast cancer. , 2015, MicroRNA.

[116]  Haidong Dong,et al.  Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.

[117]  James M. Roberts,et al.  Cloning of p27 Kip1 , a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals , 1994, Cell.

[118]  R. Crystal,et al.  A SNAIL1–SMAD3/4 transcriptional repressor complex promotes TGF-β mediated epithelial–mesenchymal transition , 2009, Nature Cell Biology.

[119]  E. Wentzel,et al.  miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. , 2009, Cancer research.

[120]  Tomohiko Ichikawa,et al.  Functional significance of aberrantly expressed microRNAs in prostate cancer , 2015, International journal of urology : official journal of the Japanese Urological Association.

[121]  Suimin Qiu,et al.  Stabilization of snail by NF-kappaB is required for inflammation-induced cell migration and invasion. , 2009, Cancer cell.

[122]  M. Kurosumi,et al.  Prognostic value of the ubiquitin ligase carboxyl terminus of the Hsc70‐interacting protein in postmenopausal breast cancer , 2016, Cancer medicine.

[123]  L. Chow,et al.  Aromatase inhibitor treatment of breast cancer cells increases the expression of let‐7f, a microRNA targeting CYP19A1 , 2012, The Journal of pathology.

[124]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[125]  P. Sun,et al.  MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells. , 2009, Biochemical and biophysical research communications.

[126]  M. Hanna,et al.  Role of miR-10b in breast cancer metastasis , 2010, Breast Cancer Research.

[127]  B. Jiang,et al.  MiR-148a inhibits angiogenesis by targeting ERBB3 , 2011, Journal of biomedical research.

[128]  G. Tsujimoto,et al.  Trastuzumab Produces Therapeutic Actions by Upregulating miR-26a and miR-30b in Breast Cancer Cells , 2012, PloS one.

[129]  J. Lewis-Wambi,et al.  Mechanisms of endocrine resistance in breast cancer: an overview of the proposed roles of noncoding RNA , 2015, Breast Cancer Research.

[130]  R. Lidereau,et al.  Down-regulation of BRCA1 expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers , 2011, EMBO molecular medicine.

[131]  P. Connell,et al.  Identification of CHIP, a Novel Tetratricopeptide Repeat-Containing Protein That Interacts with Heat Shock Proteins and Negatively Regulates Chaperone Functions , 1999, Molecular and Cellular Biology.

[132]  Sanghyuk Lee,et al.  MicroRNA genes are transcribed by RNA polymerase II , 2004, The EMBO journal.

[133]  Andrea Sottoriva,et al.  The shaping and functional consequences of the microRNA landscape in breast cancer , 2013, Nature.

[134]  G. Kroemer,et al.  Heat Shock Proteins 27 and 70: Anti-Apoptotic Proteins with Tumorigenic Properties , 2006, Cell cycle.

[135]  Tyler E. Miller,et al.  Anti-microRNA-222 (Anti-miR-222) and -181B Suppress Growth of Tamoxifen-resistant Xenografts in Mouse by Targeting TIMP3 Protein and Modulating Mitogenic Signal* , 2011, The Journal of Biological Chemistry.

[136]  S. Di Cosimo,et al.  microRNAs in breast cancer development and treatment. , 2014, Cancer treatment reviews.

[137]  A. Puisieux,et al.  TWIST1 Expression in Breast Cancer Cells Facilitates Bone Metastasis Formation , 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[138]  W. Gerald,et al.  Endogenous human microRNAs that suppress breast cancer metastasis , 2008, Nature.

[139]  James M. Roberts,et al.  Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle , 1992 .

[140]  William D. Foulkes,et al.  Re: Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer , 2004 .

[141]  Ugo Ala,et al.  MicroRNA-Antagonism Regulates Breast Cancer Stemness and Metastasis via TET-Family-Dependent Chromatin Remodeling , 2013, Cell.

[142]  Reuven Agami,et al.  Regulation of the p27Kip1 tumor suppressor by miR‐221 and miR‐222 promotes cancer cell proliferation , 2007 .

[143]  Stefan Wiemann,et al.  MicroRNA-31 Sensitizes Human Breast Cells to Apoptosis by Direct Targeting of Protein Kinase C ϵ (PKCϵ)* , 2013, The Journal of Biological Chemistry.

[144]  D. Horsfall,et al.  Androgens induce divergent proliferative responses in human breast cancer cell lines , 1995, The Journal of Steroid Biochemistry and Molecular Biology.

[145]  G. Wong,et al.  Hyaluronan-CD44 Interaction Promotes c-Src-mediated Twist Signaling, MicroRNA-10b Expression, and RhoA/RhoC Up-regulation, Leading to Rho-kinase-associated Cytoskeleton Activation and Breast Tumor Cell Invasion* , 2010, The Journal of Biological Chemistry.

[146]  X. Chen,et al.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.

[147]  Sun-Mi Park,et al.  The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. , 2008, Genes & development.

[148]  L. Pusztai,et al.  Abstract S1-09: A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer , 2015 .

[149]  R. Dickson,et al.  Roles of androgens in the development, growth, and carcinogenesis of the mammary gland , 2002, The Journal of Steroid Biochemistry and Molecular Biology.

[150]  Olufunmilayo I. Olopade,et al.  Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations , 2007, Nature Reviews Cancer.

[151]  B. Cullen,et al.  Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. , 2003, Genes & development.

[152]  Marilyn E Morris,et al.  MicroRNA-328 Negatively Regulates the Expression of Breast Cancer Resistance Protein (BCRP/ABCG2) in Human Cancer Cells , 2009, Molecular Pharmacology.

[153]  Hongwei Liang,et al.  miR-143 and miR-145 synergistically regulate ERBB3 to suppress cell proliferation and invasion in breast cancer , 2014, Molecular Cancer.

[154]  J. Baselga,et al.  Trastuzumab emtansine for HER2-positive advanced breast cancer. , 2012, The New England journal of medicine.

[155]  Meng Li,et al.  MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways , 2011, Oncogene.

[156]  Charles M Perou,et al.  MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11 , 2013, Nature Communications.

[157]  Tyler E. Miller,et al.  MicroRNA-221/222 Confers Tamoxifen Resistance in Breast Cancer by Targeting p27Kip1*♦ , 2008, Journal of Biological Chemistry.

[158]  Tony Hunter,et al.  p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21 , 1994, Cell.

[159]  G. Hannon,et al.  Processing of primary microRNAs by the Microprocessor complex , 2004, Nature.

[160]  S. Lawler,et al.  MicroRNAs in cancer: biomarkers, functions and therapy. , 2014, Trends in molecular medicine.

[161]  S. Fox,et al.  Comparative microRNA profiling of sporadic and BRCA1 associated basal-like breast cancers , 2015, BMC Cancer.

[162]  Jianfeng Xu,et al.  Open Access RESEARCH , 2010 .

[163]  J. Ribas,et al.  The transcriptional regulation of miR-21, its multiple transcripts and their implication in prostate cancer , 2010, Cell cycle.

[164]  C. Ambrosone,et al.  Novel genetic variants in microRNA genes and familial breast cancer , 2009, International journal of cancer.

[165]  Z. Ballatore,et al.  Androgen Receptor Expression in Early Triple-Negative Breast Cancer: Clinical Significance and Prognostic Associations , 2014, Cancers.

[166]  D. Iliopoulos,et al.  The negative costimulatory molecule PD‐1 modulates the balance between immunity and tolerance via miR‐21 , 2011, European journal of immunology.

[167]  Ericka Stricklin-Parker,et al.  Ann , 2005 .

[168]  K. Czaplinski,et al.  Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs. , 2004, RNA.

[169]  K. Koutsoukos,et al.  Heat Shock Protein 90 (Hsp90) Expression and Breast Cancer , 2012, Pharmaceuticals.

[170]  S. Alahari,et al.  MicroRNA and Breast Cancer: Understanding Pathogenesis, Improving Management , 2015, Non-coding RNA.

[171]  D. Baltimore,et al.  NF-κB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses , 2006, Proceedings of the National Academy of Sciences.

[172]  R. Gregory,et al.  MicroRNA biogenesis pathways in cancer , 2015, Nature Reviews Cancer.

[173]  Cynthie Wong,et al.  Experimental Therapeutics , Molecular Targets , and Chemical Biology Heat Shock Protein 90 Inhibitors : New Mode of Therapy to Overcome Endocrine Resistance , 2009 .

[174]  R. Huang,et al.  Epithelial-Mesenchymal Transitions in Development and Disease , 2009, Cell.

[175]  D. Whitley,et al.  Heat shock proteins: a review of the molecular chaperones. , 1999, Journal of vascular surgery.

[176]  R. Shiekhattar,et al.  TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing , 2005, Nature.